Results 161 to 170 of about 51,001 (340)

The association between COVID‐19 vaccines and bullous pemphigoid risk: A UK population‐based study

open access: yes
Journal of the European Academy of Dermatology and Venereology, EarlyView.
Mikolaj Swiderski   +7 more
wiley   +1 more source

Mucous Membrane Pemphigoid After Anti‐PD‐1 Therapy: Risk‐Stratified Management and Treatment Outcomes

open access: yesInternational Journal of Dermatology, Volume 65, Issue 7, Page 1376-1382, July 2026.
ABSTRACT Mucous membrane pemphigoid (MMP) following anti‐programmed cell death‐1 (PD‐1) therapy is rare but increasingly reported. Management of high‐ and low‐risk MMP in this setting and the potential oncologic trade‐offs remain poorly defined. We performed a narrative synthesis of all published cases of anti‐PD‐1‐associated MMP, following MEDLINE ...
Serena Dienes   +2 more
wiley   +1 more source

Bullous Pemphigoid [PDF]

open access: yesJAMA Dermatology, 2013
Misha, Rosenbach   +2 more
openaire   +2 more sources

Challenging cause of bullous eruption of the hands in the Arctic

open access: green, 2018
Bo Kristiansen   +2 more
openalex   +2 more sources

[Translated article] Recent-Onset Bullous Lesions

open access: gold, 2022
Laura Rodríguez-Lago   +2 more
openalex   +1 more source

European S2k guidelines on management of autoimmune blistering diseases in children and adolescents

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 40, Issue 7, Page 1137-1161, July 2026.
Autoimmune blistering disorders (AIBDs) in children are rare, challenging to diagnose and treat and often require immunosuppressants. Until now, no paediatric care guidelines existed. The EADV Task Force for AIBDs has developed the consensus‐based recommendations, enabling physicians to adopt a uniform, tailored treatment strategy to improve outcomes ...
A. Nanda   +31 more
wiley   +1 more source

Home - About - Disclaimer - Privacy